Home News

ROVI and the EIB agreement

ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies

Thu, 21/12/2017 - 18:33 0 min
No votes yet
 
Related
ROVI increases its operating revenue by 21% and EBITDA by 99%
Operating revenue increased by 21% to 177.5 million euros in the first half of 2019, mainly driven by the strength of the specialty...
6 min
30/07/2019
First half 2019 results presentation
0 min
30/07/2019
ROVI announces completion of the Clinical Trial Program that will support the...
Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the conclusion of the PRISMA-3 and BORIS  studies, thus...
5 min
05/07/2019